Related Experiment Video
Updated: Jul 16, 2026
09:03
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Recent developments in tumor angiogenesis
1Institut National de la Santé et de la Recherche Médicale E0113, Molecular Mechanisms of Angiogenesis, University Bordeaux I, Avenue des Facultés, 33405 Talence, France.
Current Pharmaceutical Biotechnology
|February 22, 2007
Summary
Blocking new blood vessel growth (angiogenesis) can fight cancer, but current research models have limitations. Optimizing these models is crucial for developing effective anti-angiogenesis therapies for cancer.
Area of Science:
- Oncology
- Developmental Biology
- Pharmacology
Background:
- Angiogenesis, the formation of new blood vessels, is vital in development, wound healing, and cancer growth.
- In cancer, inhibiting angiogenesis aims to starve tumors and promote regression.
- Anti-vascular endothelial growth factor (anti-VEGF) therapy combined with chemotherapy improves survival in cancer patients, suggesting complex anti-angiogenesis mechanisms.
Purpose of the Study:
- To evaluate the role and limitations of current angiogenesis models in cancer research.
- To highlight the need for improved models that reflect the complexity of angiogenesis in diseases like cancer.
Main Methods:
- Review of existing angiogenesis models used in preclinical and clinical research.
- Analysis of the advantages and disadvantages of current models.
Main Results:
- Current angiogenesis models have limitations and their conclusions require cautious interpretation.
- Despite limitations, these models have identified molecules for clinical trials.
Conclusions:
- Existing angiogenesis models are insufficient to fully capture the complexity of the angiogenic process in cancer.
- Optimization of current models and development of novel ones are necessary for advancing anti-angiogenesis therapies.
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...